BCM
RNAC icon

BlueCrest Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

BlueCrest Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,010
Closed -$459K – 309
2023
Q1 		$459K Buy
+11,010
New +$518K 0.02% 194

Other funds holding RNAC

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's RNAC Position: Q2 2023 in Review

BlueCrest Capital Management sold out of Cartesian Therapeutics (RNAC) in Q2 2023, closing a stake of 11,010 shares — an estimated $459K sold.

BlueCrest Capital Management first reported a position in RNAC in Q1 2023 and held it in 1 quarter. The position peaked at $459K in Q1 2023. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2023.

  • BlueCrest Capital Management reported no remaining Cartesian Therapeutics position as of Q2 2023 after selling out during the quarter.
  • BlueCrest Capital Management sold 11,010 Cartesian Therapeutics shares in Q2 2023, an estimated $459K.
  • BlueCrest Capital Management first reported a position in Cartesian Therapeutics in Q1 2023 and held it in 1 quarter.
  • BlueCrest Capital Management's Cartesian Therapeutics position peaked at $459K in Q1 2023.
  • 92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2023.

Based on BlueCrest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.